Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals delists from Nasdaq to focus on clinical trials, cutting compliance costs and sharpening its migraine and addiction drug pipeline.

Read how Anebulo Pharmaceuticals’ oversubscribed share repurchase boosted its stock and signals strong investor confidence.

Anebulo Pharmaceuticals, a clinical-stage biotech company, has announced plans to go private, leading to a surge in its stock price and a potential restructuring of its financial standing.